High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection

Journal of Infectious Diseases

Volumn 201, Issue 2, 2010, Pages 285-292

  Baker, Jason ^a,c   Ayenew, Woubeshet ^a,c   Quick, Harrison ^b   Hullsiek, Katherine Huppier ^b   Tracy, Russell ^d   Henry, Keith ^a,c   Duprez, Daniel ^a   Neaton, James D ^b  

^a Pennsylvania State University   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VERMONT   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TRIACYLGLYCEROL; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; MIDDLE AGED; THROMBOSIS; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HIV INFECTIONS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; THROMBOSIS;

EID: 75649105079     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649560     Document Type: Article

References (50)

1. Baker JV, Henry K, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009; 4:176-182
2. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8:737-741
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular diseaseP: four prospective American studies. Circulation 1989;79:8-15.
4. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vase Biol 1997; 17:107-113
5. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982
6. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772
7. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26: 847-870
8. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs HighDensity Lipoprotein Intervention Trial. Circulation 2006; 113:1556-1563
9. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009; 116:87-98.
10. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vase Biol 1998; 18:1046-1053
11. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vase Biol 2002; 22: 1175-1180
12. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002; 90:89-94.
13. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007; 195:122-128
14. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296
15. Phillips A, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187
16. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
17. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009 [epub ahead of print].
18. 100. National Heart Lung and Blood Institute. Risk assessment tool for estimating your 10 year risk of having a heart attack. Available at: http://hp2010.nhlbihin.net/atpiii/calculator.asp. Accessed 18 November 2009.
19. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: as- sessment and implications for epidemiology. Am J Epidemiol 1999; 149:261-267
20. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6, C-reative protein levels with mortality in the elderly. Am J Med 1999; 106:506-512
21. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk fo future myocardial infarction among apparently healthy men. Circulation 2000; 2000:1767.
22. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middleaged men and women. The Scottish Heart Health Study. European Heart Journal 1998; 19:55-62.
23. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vase Biol 1999; 19:493-498
24. Cohen HJ, Harris TB, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114:180-187
25. Jenny NS, Arnold AM, Kuller LH, et al. Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost 2006; 4:107-113
26. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112:3080-3087
27. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-I, ICAM-I, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96:4219-4225
28. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Creactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112:976-983
29. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749
30. Grundy SM, Brewer HB Jr., Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438
31. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1 -infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008;48:281-288
32. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168:195-211.
33. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 144-153
34. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23:370-378
35. Neuhaus J, Jacobs DR; the SMART/INSIGHT M and CARDIA Study Groups. Markers of inflammation, coagulation, and renal function in HIV-infected adults in SMART and in two large population-based stdies, CARDIA and MESA [abstract 740], In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
36. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004;4:213-222
37. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707-715
38. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181(Suppl 3):S462-72.
39. Mineo C, Deguchi H, Griffin JH, Shaul PW Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364
40. Viswambharan H, Ming XF, Zhu S, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 2004; 94:918-925
41. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
42. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86.
43. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008; 22:4044-4054
44. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL: an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2:504-511
45. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92.
46. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost 1999; 82:826-831
47. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843 (Pubitemid 30165206)
48. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-1342
49. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103:2323-2327
50. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565